Overview
Biotechnology firm reported a $0.06 net loss per share for Q4
Completed enrollment for OCU400 Phase 3 clinical trial
Outlook
Ocugen expects topline Phase 3 data for OCU400 in Q1 2027
Company anticipates interim data for OCU410ST trial in Q3 2026
Result Drivers
HIGHER R&D EXPENSES: Research and development expenses for the three months ended December 31, 2025, were $10.7 million compared to $8.3 million for the three months ended December 31, 2024
Company press release: ID:nGNX4RNMSL
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.06
Q4 Net Income
-$17.71 mln
Q4 Operating Expenses
$16.80 mln
Q4 Profit From Operations
-$17 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Ocugen Inc is $8.00, about 330.1% above its March 3 closing price of $1.86
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
